Bio-Rad Laboratories has broadened its collection of recombinant monoclonal anti-idiotypic antibodies, adding specificities ...

GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...

GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...

Use of belimumab prior to vs after initiating immunosuppressants was linked to faster OGC tapering and fewer disease flares among patients with SLE.

In a report released today, Steve Scala from TD Cowen maintained a Hold rating on GlaxoSmithKline. The company’s shares closed yesterday at $37.67. Take advantage of TipRanks Premium at 50% off!

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline today and set a price target of £13.97. The company’s shares opened today at p1,424.50. Take advantage of TipRanks Premium ...

With this approval, GSK is expanding choices for belimumab treatment, offering pediatric lupus nephritis patients and caregivers a first-of-its-kind subcutaneous option that can be administered at ...

PHILADELPHIA, June 24, 2025--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a 200 mg/mL autoinjector of Benlysta (belimumab), a B-lymphocyte ...

Belimumab, a monoclonal antibody, added to standard therapy may treat a broader range of patients with lupus nephritis than previously appreciated.

Belimumab is under clinical development by GSK and currently in Phase III for Rheumatoid Arthritis.

Belimumab demonstrated superior efficacy vs placebo for achieving remission and low disease activity status among patients with active SLE.

Compared with placebo plus standard therapy, belimumab plus standard therapy led to higher rates of remission and low disease activity in patients with moderate to severe SLE.